The Comprehensive Digestive Stool Analysis
(CDSA) is the original non-invasive evaluation of gastrointestinal function that includes analyses of digestion,
absorption, bacterial balance, yeast and parasites. This profile is recommended for patients with diffuse and
non-specific GI-related symptoms, such as indigestion, dysbiosis, constipation, and diarrhea.
Comprehensive Digestive Stool Analysis (CDSA)
2.0 uses advanced GI biotechnology to evaluate digestion, absorption, pancreatic function, and inflammation, in
addition to bacterial balance, yeast, and parasite infection. This profile features exclusive new markers for assessing
irritable bowel syndrome, sub-mucosal inflammation, colorectal cancer risk, pancreatic insufficiency, and occult
infection.
Comprehensive Parasitology Profile evaluates stool
for presence of parasites and levels of beneficial flora, imbalanced flora, pathogenic bacteria, and yeast. For patients
with abdominal pain, chronic diarrhea, and other GI-related symptoms.
Intestinal Permeability Assessment analyzes urine for the
clearance of two non-metabolized sugars, lactulose and mannitol. Identifies "leaky gut" and malabsorption.
Lactose Intolerance Breath Test is a
simple, noninvasive test, detects lactose intolerance, a condition affecting more than 50 million Americans. Proper
detection enables effective treatment of lactose maldigestion and malabsorption to help alleviate chronic symptoms of
bloating, gas, diarrhea, and abdominal pain.
Bacterial Overgrowth of the Small Intestine
Breath Test is a simple, noninvasive test that detects bacterial overgrowth in the small intestine, a common
condition that often underlies chronic symptoms of maldigestion and malabsorption, including bloating, gas, diarrhea,
irregularity, and abdominal pain.
Heliobacter pylori Stool Antigen test is an
FDA - approved evaluation of H. pylori antigens shed directly in the stool. This test is useful for detecting the major
causal bacterium associated with peptic ulcers, chronic gastritis, and increased risk of gastric cancer. This
noninvasive test also provides a simple and sensitive clinical tool for monitoring eradication therapy.
Vaginosis Profile uses a new DNA probe to identify
clinically significant levels of Candida, Gardnerella, and Trichomonas. The profile also evaluates levels of beneficial
flora and yeast, cytosis, leukocytes, and RBCs. A measurement of eosinophils may also be included.
